Stroke
📧 Sign up to get email alerts when something new happens for Stroke.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-25EMA Authorised: Svariya (previously Rivaroxaban Koanaa) (rivaroxaban) — Koanaa Healthcare GmbH
EMA authorised Svariya (rivaroxaban) for prevention and treatment uses related to thromboembolic conditions; managed by Koanaa Healthcare Gm…
-
EMA approval · 2026-08-03EMA Authorised: Clopidogrel Zentiva (previously Clopidogrel Winthrop) (clopidogrel) — Zentiva k.s.
Authorisation granted for Clopidogrel Zentiva (clopidogrel), expanding or confirming its availability for stroke, peripheral vascular diseas…
-
EMA approval · 2026-07-27EMA Authorised: Apixaban Accord (apixaban) — Accord Healthcare S.L.U.
Authorised status for Apixaban Accord (apixaban) by Accord Healthcare S.L.U. for venous thromboembolism, stroke, and arthroplasty indication…
-
EMA approval · 2026-04-20EMA Authorised: Lixiana (edoxaban tosilate) — Daiichi Sankyo Europe GmbH
The EMA authorised Lixiana (edoxaban tosilate) from Daiichi Sankyo Europe GmbH for indications related to stroke and venous thromboembolism.
-
EMA approval · 2026-04-20EMA Authorised: Roteas (edoxaban tosilate) — Berlin-Chemie AG
The European Medicines Agency authorised Roteas, a product containing edoxaban, for indications related to stroke prevention and venous thro…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-02-24EMA Authorised: Apixaban Accord (apixaban) — Accord Healthcare S.L.U.
The European Medicines Agency authorised Apixaban Accord (apixaban) from Accord Healthcare S.L.U. for indications in venous thromboembolism,…
-
FDA approval · 2026-02-18FDA Approved: ARBLI — Supplemental Application (Scienture LLC)
FDA approved a supplemental application for ARBLI (losartan potassium) filed by Scienture LLC.
-
EMA approval · 2026-02-05EMA Authorised: Clopidogrel Zentiva (previously Clopidogrel Winthrop) (clopidogrel) — Zentiva k.s.
The European Medicines Agency authorised Zentiva’s generic clopidogrel product for prevention of stroke, myocardial infarction, acute corona…
-
EMA approval · 2025-12-17EMA Authorised: Rivaroxaban Koanaa (rivaroxaban) — Koanaa Healthcare GmbH
The European Medicines Agency authorised Koanaa Healthcare GmbH's rivaroxaban product, Koanaa, for indications including venous thromboembol…
-
FDA approval · 2025-12-16FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved a supplemental application for Camber Pharmaceuticals' Losartan Potassium (generic Losartan Potassium). The approval authorizes…
-
EMA approval · 2025-12-12EMA Authorised: Clopidogrel Viatris (previously Clopidogrel Taw Pharma) (clopidogrel besilate) — Viatris Limited
The EMA has authorized Clopidogrel Viatris (clopidogrel besilate) for use in preventing thrombotic events in patients with peripheral vascul…
-
EMA approval · 2025-11-05EMA Authorised: Rivaroxaban Viatris (previously Rivaroxaban Mylan) (rivaroxaban) — Viatris Limited
The EMA authorised Viatris Limited to market rivaroxaban (brand name Rivaroxaban Viatris), expanding access to this anticoagulant as a gener…
-
FDA approval · 2025-10-28FDA Approved: TICAGRELOR — Original Application (Oryza Pharmaceuticals, Inc.)
FDA approved the ticagrelor product from Oryza Pharmaceuticals, Inc. under its original application (ANDA 208508).
-
EMA approval · 2025-08-28EMA Authorised: Rivaroxaban Accord (rivaroxaban) — Accord Healthcare S.L.U.
The EMA authorised Accord Healthcare's rivaroxaban product (Rivaroxaban Accord) for multiple indications including acute coronary syndrome, …
-
EMA approval · 2025-08-26EMA Authorised: Iscover (clopidogrel) — Sanofi Winthrop Industrie
The European Medicines Agency has authorised Iscover, a clopidogrel product from Sanofi Winthrop Industrie, for preventing thrombotic events…
-
FDA approval · 2025-08-01FDA Approved: CLOPIDOGREL — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for clopidogrel from Amneal Pharmaceuticals LLC under the ANDA process (generic product).
-
EMA approval · 2025-07-14EMA Authorised: Plavix (clopidogrel hydrogen sulfate) — Sanofi Winthrop Industrie
The EMA authorised Plavix (clopidogrel hydrogen sulfate) for use with indications including stroke, peripheral vascular disease, atrial fibr…
-
EMA approval · 2025-06-23EMA Authorised: Grepid (clopidogrel (as besilate)) — Pharmathen S.A.
EMA authorised the drug Grepid, containing clopidogrel besilate, for indications including peripheral vascular diseases, stroke, and myocard…
-
EMA approval · 2025-05-14EMA Authorised: Clopidogrel Krka (clopidogrel (as hydrochloride)) — Krka, d.d., Novo mesto
EMA authorised Clopidogrel Krka (clopidogrel hydrochloride) on 14 May 2025 for reducing cardiovascular events in patients with peripheral ar…
-
EMA approval · 2025-05-14EMA Authorised: Zyllt (clopidogrel (as hydrogen sulfate)) — Krka, d.d., Novo mesto
EMA authorised Zyllt, a clopidogrel hydrogen sulfate product by Krka, d.d., Novo mesto. It is indicated for preventing vascular events in pa…
-
EMA approval · 2025-05-13EMA Authorised: Clopidogrel Krka d.d. (previously Zopya) (clopidogrel (as hydrochloride)) — Norpharm Regulatory Services Ltd
The EMA authorised Clopidogrel Krka d.d. for indications including peripheral vascular disease, stroke, and myocardial infarction; the marke…
-
EMA approval · 2025-05-13EMA Authorised: Clopidogrel TAD (clopidogrel (as hydrochloride)) — Tad Pharma GmbH
EMA authorised Clopidogrel TAD (clopidogrel hydrochloride) by Tad Pharma GmbH for use in peripheral vascular diseases, stroke, and myocardia…
-
FDA approval · 2025-02-25FDA Approved: CLOPIDOGREL — Supplemental Application (NorthStar RxLLC)
FDA approved a supplemental application for clopidogrel filed by NorthStar RxLLC under an ANDA. The action indicates regulatory clearance fo…
-
EMA approval · 2024-03-26EMA Authorised: Clopidogrel ratiopharm (clopidogrel (as hydrogen sulfate)) — Teva B.V.
European Medicines Agency authorises Clopidogrel ratiopharm (clopidogrel hydrogen sulfate) for multiple cardiovascular indications including…
-
EMA approval · 2024-02-29EMA Authorised: Clopidogrel Teva (hydrogen sulphate) (clopidogrel (as hydrogen sulfate)) — Teva Pharma B.V.
EMA authorised Clopidogrel Teva (hydrogen sulphate) for multiple cardiovascular indications including acute coronary syndrome, myocardial in…